Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
about
Intraocular lymphoma: a clinical perspectiveBeyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaCentral nervous system prophylaxis in diffuse large B-cell lymphoma.Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomeHigh-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.Progress in central nervous system lymphomas.Correlation of diffusion MRI with the Ki-67 index in non-small cell lung cancerParametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationPrimary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experienceCXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphomaNew approaches in primary central nervous system lymphoma.Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).How I treat CNS lymphomas.Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.Diagnosis and treatment of primary CNS lymphoma.High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.The Challenge of Primary Central Nervous System Lymphoma.Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer.Advances in the treatment of newly diagnosed primary central nervous system lymphomas.Reply to M.C. Chamberlain.Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report.Atypical imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas in patients without AIDS.Biology of CNS lymphoma and the potential of novel agents.Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status.Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma Treatment Response.Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).Whole Tumor Histogram-profiling of Diffusion-Weighted Magnetic Resonance Images Reflects Tumorbiological Features of Primary Central Nervous System Lymphoma.Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.Apparent diffusion coefficient histogram in breast cancer brain metastases may predict their biological subtype and progression.Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
P2860
Q26827115-3C33D9E3-8EA0-4554-BA02-FF3A7DCE98B8Q27013785-18786827-3202-41F7-8503-546EEBDA4D5BQ30251550-59153897-556B-496A-8171-17C381249E85Q30457046-5DE5C237-A5D3-4EA8-9A59-7077778F5693Q33427514-B97D16E6-74D0-4073-A456-63FC82D59CCEQ33934406-949A3199-0F09-4BE2-8795-95A6DAD25009Q36079254-87A91DD3-E965-4837-85B4-AF0438E7FCB3Q36279602-CEBCCDF5-CE31-4FAC-8E3D-7E8D88120D65Q36805865-FD36740B-61D7-4C37-8AD8-8964EFA5E7F3Q36825376-8A23A5F8-4DB3-4E1B-8154-692B43306CCEQ36907849-4EAD261E-279C-4B9D-B5F6-FC7EE4DED161Q37088471-61E19BFD-E80B-4DE6-8E89-1CAD913D5CF0Q37122287-4B441C08-05C9-422E-9CF9-AEBA4A9C3ACFQ37215118-76A7C564-CBEC-499F-9555-DBE18D26F502Q37687767-A4F29125-D7C1-4495-9596-A933DF0E5075Q38106613-A5E2CE3D-8F2F-4AFD-80E4-CCE9D1A34D39Q38859813-748D27CA-5CDA-4428-8F6F-B635A641406DQ39020652-649BC654-54EC-4C28-BF93-0417D9090E92Q39030177-D271B7D8-04B5-4A34-90A7-5FCAF6E717CEQ41881716-42910EBF-C761-4C71-BF52-63DF079E732EQ42377771-B0C2F544-8F46-47BD-937F-3622F5BBD1CBQ42426074-0D740248-C790-49D7-84EC-29EA7B6FEBEBQ44600425-B539090E-92BA-4843-984C-053CD0599D01Q45352584-0CF18B81-AAFB-4F90-A78B-547C9C5B3138Q45985951-36531C4B-A9C5-4FD8-9D15-0131B20C50D7Q47136050-364584E1-7807-45FD-ACDA-5717CCF5079FQ47208190-924BD5BE-D2D3-4302-B7F0-B8497E1A793CQ47790904-98ECE66D-DC10-4C9D-A12F-3E04F326A0E7Q48168887-10F18944-67F5-427A-B5CD-3CE8055E8B1CQ49330513-AA139AE3-DBEE-46F0-897A-5F42A8B45885Q55341200-4E71FABC-FB41-4FEB-94B9-F08AFC19F772Q55350679-24485041-B81E-48A2-9CDA-01D5DFE4FC5DQ55517537-BC9EE39E-06F5-452C-AA5B-FFE9407E9F03Q55688305-49E2D9CC-82B2-42A9-96C5-428B407297BC
P2860
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@ast
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@en
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@en-gb
type
label
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@ast
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@en
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@en-gb
prefLabel
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@ast
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@en
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@en-gb
P2093
P2860
P1476
Immunochemotherapy with intens ...... ent by diffusion-weighted MRI.
@en
P2093
Caroline M Behler
Francisco Valles
James Hwang
James L Rubenstein
Joan O'Brien
Lloyd E Damon
Marc A Shuman
Matthew J Wieduwilt
Patrick Treseler
Samar Issa
P2860
P304
P356
10.1158/1078-0432.CCR-11-0625
P407
P577
2012-01-06T00:00:00Z